New Therapeutic Possibilities of Type 2 Diabetes Mellitus Management: Experience of Voglibose Application

Main Article Content

V.I. Pankiv


Objective of the study — an estimation of efficiency of application and tolerability of new alpha-glucosidase inhibitor voglibose (Voxid) in the treatment of patients with type 2 diabetes mellitus (DM). Material and Methods. We have examined 20 patients with type 2 DM aged from 32 to 65 years, who did not have satisfactory glycemic control during previous treatment. Before the beginning of research and during all supervision they received previous hypoglycemic therapy (metformin and glimepiride). The total duration of patients’ participation in the study was 3 months and included four visits: an initial visit, the first and second months — interim visits; 3 months later — the final visit. HbА1c was measured during the first and last visits. Patients with type 2 DM were additionally administered voglibose (Voxid, produced by LLC «Kusum Pharm», Ukraine) at a dose of 0.2 mg before breakfast, lunch and dinner for three months as a part of combination oral hypoglycemic therapy. Results. After 3 months of voglibose application, fasting glucose content decreased by 1.8 mmol/l and was 7.4 ± 0.3 mmol/l. During the fourth visit, the level of postprandial blood glucose against combined therapy with the addition of Voxid significantly decreased by 2.6 mmol/l, НbA1c — by 1.2 %. There was a trend to a decrease in body mass index in surveyed patients (by 1.1 kg/m2), but it did not reach statistical significance. The positive clinical effect of the drug in ours study was achieved at an average of 0.75 mg Voxid a day. Treatment with Voxid was safe for patients and well tolerated. Conclusions. Application of Voxid (voglibose) in combination therapy of type 2 DM for three months resulted in a statistically significant improvement in the main indicators of metabolism and insulin resistance reduction.

Article Details

How to Cite
Pankiv, V. “New Therapeutic Possibilities of Type 2 Diabetes Mellitus Management: Experience of Voglibose Application”. INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine), no. 6.62, Oct. 2014, pp. 51-54, doi:10.22141/2224-0721.6.62.2014.76937.
To practicing Endocrinologists


Паньків В.І. Інгібітор альфа-глюкозидази воглібоз: нові можливості лікування і профілактики цукрового діабету // Міжнародний ендокринологічний журнал. — 2013. — № 7(55). — С. 35-38.

Kumar R.V., Sinha V.R. Newer insights into the drug delivery approaches of α-glucosidase inhibitors // Expert. Opin. Drug. Deliv. — 2012. — Vol. 9(4). — P. 403-416.

Takami K., Takeda N., Nakashima K. et al. Effects of dietary treatment alone or diet with voglibose or glyburide on abdominal adipose tissue and metabolic abnormalities in patients with newly diagnosed type 2 diabetes. // Diabetes Care. — 2002. — Vol. 25(4). — P. 658-662.

Matsumoto K., Yano M., Miyake S. et al. Effects of voglibose on glycemic excursions, insulin secretion, and insulin sensitivity in non-insulin-treated NIDDM patients // Diabetes Care. — 1998. — 21(2) Feb. — 256-60.

Chen X., Zheng Y., Shen Y. Voglibose (Basen, AO-128), one of the most important alpha-glucosidase inhibitors // Curr. Med. Chem. — 2006. — 13(1). — 109-16.

Most read articles by the same author(s)

1 2 3 4 5 6 7 8 9 10 11 > >>